Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...
Animate Biosciences today announces new preclinical results demonstrating that AI-designed peptides generated by its AnimateIQ™ discovery platform significantly reduced hallmark inflammation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback